The development of synthetic peptidolipids, glycolipids and other lipid-linked structures to create designer red cells
| aut.relation.endpage | 195A | |
| aut.relation.issue | 2 | |
| aut.relation.startpage | 194A | |
| aut.relation.volume | 48 | |
| aut.researcher | Henry, Stephen Micheal | |
| dc.contributor.author | Henry, S | |
| dc.contributor.author | Bovin, N | |
| dc.date.accessioned | 2012-05-13T20:31:05Z | |
| dc.date.available | 2012-05-13T20:31:05Z | |
| dc.date.copyright | 2008-09 | |
| dc.date.issued | 2008-09 | |
| dc.description.abstract | Background: Red cells used in immunohematology assays are restricted by their natural phenotype and membrane characteristics. More recently a technology has been developed which allows for the attachment of a large variety of specific carbohydrates, peptides and other structures to the surface of cells – known as FSL cell surface coating (KODETM technology). FSL constructs are water dispersible and consist of three components; a F functional head group, a S spacer and a L diacyl lipid tail. This technology allows users to introduce novel antigen profiles or characteristics at the membrane surface of cells. Methods: FSL constructs were synthesised bearing carbohydrates, peptides, and fluorophores. One part (0.05 ml) of FSL construct 1 mg/ml and one part of packed red cells were combined, mixed and incubated at 37°C for 2 hours, washed and then analysed for the presence of constructs by direct-indirect agglutination and fluorescence serological methods. Results: In all cases red cells were shown to be able to be precisely labelled with serologically detectable FSL construct. Red cells were modified to carry ABO, H, Lewis, acquired-B, the animal antigen Galili, hyaluronic acid, fluorophores and blood group peptides (Miltenberger). Conclusion: FSL cell surface coating technology allows for the creation of red cells expressing controlled levels of normal and/or novel antigens or structures. Such cells can be used for quality control, specialised antibody screening and identification panels and have potential for novel future applications. | |
| dc.identifier.citation | Transfusion 2008; 48 (2S) Suppl.: 194A | |
| dc.identifier.doi | 10.1111/j.1537-2995.2008.01891.x | |
| dc.identifier.issn | 0041-1132 | |
| dc.identifier.uri | https://hdl.handle.net/10292/4136 | |
| dc.publisher | John Wiley & Sons | |
| dc.rights | Copyright © 2008 John Wiley & Sons. All rights reserved. Authors retain the right to place his/her pre-publication version of the work on a personal website or institutional repository. This article may not exactly replicate the final version published in (please see citation) as it is not a copy of this record. An electronic version of this article can be found online at: (Please see Publisher’s Version) | |
| dc.rights.accessrights | OpenAccess | |
| dc.title | The development of synthetic peptidolipids, glycolipids and other lipid-linked structures to create designer red cells | |
| dc.type | Conference Contribution | |
| pubs.organisational-data | /AUT | |
| pubs.organisational-data | /AUT/Health & Environmental Science | |
| pubs.organisational-data | /AUT/PBRF Researchers | |
| pubs.organisational-data | /AUT/PBRF Researchers/Health & Environmental Sciences PBRF Researchers | |
| pubs.organisational-data | /AUT/PBRF Researchers/Health & Environmental Sciences PBRF Researchers/HES Applied Science |